Cargando…

Prognostic Nomogram and Therapeutic Option of Cancer-Specific Death in the Patients with Metachronous Second Primary Lung Cancer

With the increase of long-term primary lung cancer survivors, studies focused on metachronous second primary lung cancer (SPLC) have become very urgent. This study aimed to develop a prognostic nomogram and determine therapeutic options of cancer-specific death for patients with metachronous SPLC wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiahui, Chen, Zhen, Xia, Daokui, Song, Xinyu, Hu, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789464/
https://www.ncbi.nlm.nih.gov/pubmed/35087587
http://dx.doi.org/10.1155/2022/2819798
_version_ 1784639769821577216
author Wang, Jiahui
Chen, Zhen
Xia, Daokui
Song, Xinyu
Hu, Zhigang
author_facet Wang, Jiahui
Chen, Zhen
Xia, Daokui
Song, Xinyu
Hu, Zhigang
author_sort Wang, Jiahui
collection PubMed
description With the increase of long-term primary lung cancer survivors, studies focused on metachronous second primary lung cancer (SPLC) have become very urgent. This study aimed to develop a prognostic nomogram and determine therapeutic options of cancer-specific death for patients with metachronous SPLC with and without the competing risk of other-specific death. Study population came from the SEER-18 database between 2006 and 2016. According to the clinical practice guideline of SPLC, the interval time of IPLC and metachronous SPLC was set to 4 years. We constructed nomograms with Lasso + Cox regression model and competing risk model to predict the prognosis and identify therapeutic options of metachronous SPLC patients with the assessment of model performance by the C-index, calibration plot, and decision curve analysis. In addition, two subgroup analyses stratified by histology and tumor size were used to better select therapeutic options for a certain population. 1300 patients with metachronous SPLC were incorporated in this study with 50.1% of the 5-year cumulative incidence in cancer-specific death. Compared with Lasso + Cox regression analysis, competing risk analysis harbored a higher C-index (0.811 vs. 0.76) and better net benefit in predicting cancer-specific death of metachronous SPLC. Two statistical analyses suggested that surgery alone was a preferentially therapeutic option of metachronous SPLC, whereas the effect of surgery + radiation in treating metachronous SPLC was similar to radiation alone. Subgroup analyses indicated that patients with metachronous SPLC were considered receiving different therapeutic options in different histology and tumor size but preferred to receive surgical treatment as the first choice. For primary lung cancer survivors, aggressive surgical treatment was the first-line selection of metachronous SPLC, followed by radiation alone, surgery + radiation, and no surgery + radiation.
format Online
Article
Text
id pubmed-8789464
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-87894642022-01-26 Prognostic Nomogram and Therapeutic Option of Cancer-Specific Death in the Patients with Metachronous Second Primary Lung Cancer Wang, Jiahui Chen, Zhen Xia, Daokui Song, Xinyu Hu, Zhigang J Oncol Research Article With the increase of long-term primary lung cancer survivors, studies focused on metachronous second primary lung cancer (SPLC) have become very urgent. This study aimed to develop a prognostic nomogram and determine therapeutic options of cancer-specific death for patients with metachronous SPLC with and without the competing risk of other-specific death. Study population came from the SEER-18 database between 2006 and 2016. According to the clinical practice guideline of SPLC, the interval time of IPLC and metachronous SPLC was set to 4 years. We constructed nomograms with Lasso + Cox regression model and competing risk model to predict the prognosis and identify therapeutic options of metachronous SPLC patients with the assessment of model performance by the C-index, calibration plot, and decision curve analysis. In addition, two subgroup analyses stratified by histology and tumor size were used to better select therapeutic options for a certain population. 1300 patients with metachronous SPLC were incorporated in this study with 50.1% of the 5-year cumulative incidence in cancer-specific death. Compared with Lasso + Cox regression analysis, competing risk analysis harbored a higher C-index (0.811 vs. 0.76) and better net benefit in predicting cancer-specific death of metachronous SPLC. Two statistical analyses suggested that surgery alone was a preferentially therapeutic option of metachronous SPLC, whereas the effect of surgery + radiation in treating metachronous SPLC was similar to radiation alone. Subgroup analyses indicated that patients with metachronous SPLC were considered receiving different therapeutic options in different histology and tumor size but preferred to receive surgical treatment as the first choice. For primary lung cancer survivors, aggressive surgical treatment was the first-line selection of metachronous SPLC, followed by radiation alone, surgery + radiation, and no surgery + radiation. Hindawi 2022-01-18 /pmc/articles/PMC8789464/ /pubmed/35087587 http://dx.doi.org/10.1155/2022/2819798 Text en Copyright © 2022 Jiahui Wang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Jiahui
Chen, Zhen
Xia, Daokui
Song, Xinyu
Hu, Zhigang
Prognostic Nomogram and Therapeutic Option of Cancer-Specific Death in the Patients with Metachronous Second Primary Lung Cancer
title Prognostic Nomogram and Therapeutic Option of Cancer-Specific Death in the Patients with Metachronous Second Primary Lung Cancer
title_full Prognostic Nomogram and Therapeutic Option of Cancer-Specific Death in the Patients with Metachronous Second Primary Lung Cancer
title_fullStr Prognostic Nomogram and Therapeutic Option of Cancer-Specific Death in the Patients with Metachronous Second Primary Lung Cancer
title_full_unstemmed Prognostic Nomogram and Therapeutic Option of Cancer-Specific Death in the Patients with Metachronous Second Primary Lung Cancer
title_short Prognostic Nomogram and Therapeutic Option of Cancer-Specific Death in the Patients with Metachronous Second Primary Lung Cancer
title_sort prognostic nomogram and therapeutic option of cancer-specific death in the patients with metachronous second primary lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789464/
https://www.ncbi.nlm.nih.gov/pubmed/35087587
http://dx.doi.org/10.1155/2022/2819798
work_keys_str_mv AT wangjiahui prognosticnomogramandtherapeuticoptionofcancerspecificdeathinthepatientswithmetachronoussecondprimarylungcancer
AT chenzhen prognosticnomogramandtherapeuticoptionofcancerspecificdeathinthepatientswithmetachronoussecondprimarylungcancer
AT xiadaokui prognosticnomogramandtherapeuticoptionofcancerspecificdeathinthepatientswithmetachronoussecondprimarylungcancer
AT songxinyu prognosticnomogramandtherapeuticoptionofcancerspecificdeathinthepatientswithmetachronoussecondprimarylungcancer
AT huzhigang prognosticnomogramandtherapeuticoptionofcancerspecificdeathinthepatientswithmetachronoussecondprimarylungcancer